Alnylam Pharmaceuticals

1261 articles about Alnylam Pharmaceuticals

• Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference

  5/3/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas.

• Alnylam Issues 2022 Corporate Responsibility Report

  5/3/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report.

• Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  4/26/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

• Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

  4/26/2023

  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

• 

  Ionis and AstraZeneca Seek to Challenge Alnylam with New ATTR Data

  4/24/2023

  Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.

• Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results

  4/20/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.

• Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

  3/9/2023

  Alnylam Pharmaceuticals, Inc. and Medison Pharma have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. 

• Alnylam Announces Appointment of Peter Kellogg to Board of Directors

  3/8/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors.

• Alnylam to Webcast Presentations at Upcoming March Investor Conferences - March 1, 2023

  3/1/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences.

• Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

  2/23/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.

• Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

  2/21/2023

  Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis.

• Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

  2/2/2023

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.

• 

  Remote Work, Consolidation Potential Detractors for Boston

  1/30/2023

  At a panel Friday, "Boston's Booming Biotech System," experts from industry and academia weighed in on the financial repercussions of 2022 and what it portends for 2023.

• Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

  1/8/2023

  Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.

• Alnylam Announces Updates to its Board of Directors

  1/5/2023

  Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announces appointment of Carolyn Bertozzi, Ph.D. a Nobel Laureate to the Board.

• Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT at The Westin St. Francis in San Francisco.

• 

  Voyager's Al Sandrock, Alnylam's Yvonne Greenstreet and More Share Their Predictions for 2023

  12/23/2022

  BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.

• Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes

  12/21/2022

  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase.

• Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

  12/15/2022

  Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, is hosting a virtual R&D Day today.

• Alnylam to Webcast Virtual R&D Day

  12/8/2022

  Alnylam Pharmaceuticals, Inc. announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on December 15, 2022 at 8:30 am ET.